Our Cell Processing Facility is a GMP bioprocessing manufacturing facility that supports the reproducible, compliant production of human hematopoietic or immune-competent cells for Phase 1/2 clinical trials under stringent quality control and safety requirements.
Our Biologics Production Facility provides both preclinical and clinical (Phase 1) cGMP manufacturing capabilities for cellular-based products from eukaryotic and prokaryotic culture systems, including monoclonal antibodies, fusion proteins, conjugates, plasmids, viral vectors and peptide vaccines.
Our quality team is responsible for the execution of suitable methods to characterize our Phase 1/2 cell therapy and biologics products, and for managing our quality management system. We ensure that all our products are fit for intended use.